Advertisement

Advertisement

2016 Pan Pacific Lymphoma Conference

lymphoma

James O. Armitage, MD, on Improving Lymphoma Treatment

James O. Armitage, MD, of the University of Nebraska Medical Center, discusses how an increased understanding of the biology of lymphomas and their multiple subtypes has had a major impact on the abil...

multiple myeloma

S. Vincent Rajkumar, MD, and Sagar Lonial, MD, on Treating Multiple Myeloma

S. Vincent Rajkumar, MD, of the Mayo Clinic, and Sagar Lonial, MD, of the Emory University School of Medicine, discuss key issues in treating this disease, including monoclonal antibodies, plasmacytom...

lymphoma

Nathan Fowler, MD, and Sagar Lonial, MD, on Treating Follicular Lymphoma

Nathan H. Fowler, MD, of University of Texas MD Anderson Cancer Center, and Sagar Lonial, MD, of the Emory University School of Medicine, discuss managing early relapsing/refractory disease.

lymphoma

Steven P. Treon, MD, PhD, on Treating Lymphoplasmacytic Lymphoma/Waldenström’s Macroglobulinemia

Steven P. Treon, MD, PhD, of the Dana-Farber Cancer Institute, discusses the question of what is the best upfront therapy for lymphoplasmacytic lymphoma/Waldenström’s macroglobulinemia.

lymphoma

Jonathan W. Friedberg, MD: Marginal Zone Lymphoma Therapy Update

Jonathan W. Friedberg, MD, of the University of Rochester Medical Center, discusses the use of rituximab as a single agent and in combination with chemotherapy, the emerging role of novel agents, and ...

lymphoma

Steven M. Horwitz, MD, on Sequencing New Agents in Relapsed Peripheral T-Cell Lymphoma

Steven M. Horwitz, MD, of Memorial Sloan Kettering Cancer Center, reviews the data supporting current treatment approaches for T-cell lymphomas and discusses the specific subtype criteria used to indi...

lymphoma

Richard I. Fisher, MD, on Defining and Treating Grey Zone Lymphoma

Richard I. Fisher, MD, of Fox Chase Cancer Center-Temple Health, discusses this rare disease––with features between classical Hodgkin lymphoma and primary mediastinal large B-cell lymphoma––and review...

lymphoma

Wyndham H. Wilson, MD, PhD, on Treating Diffuse Large B-Cell Lymphoma

Wyndham H. Wilson, MD, PhD, of the National Cancer Institute, discusses the molecular underpinnings of diffuse large B-cell lymphoma and targeted treatments.

lymphoma

Fredrick B. Hagemeister, Jr, MD, on Using Rituximab Maintenance

Fredrick B. Hagemeister, Jr, MD, of the University of Texas MD Anderson Cancer Center, discusses whether rituximab maintenance should be used in indolent lymphomas other than follicular.

Julie M. Vose, MD, MBA, on Basket Trials

Julie M. Vose, MD, MBA, of the University of Nebraska Medical Center, discusses this evolution of clinical trials, and using genomic methods to direct therapy.

lymphoma

John G. Gribben, MD, DSc, on Follicular Lymphoma: Still a Role for Transplant?

John G. Gribben, MD, DSc, of Barts Cancer Institute, discusses the pros and cons of both autologous and allogeneic stem cell transplantation in follicular lymphoma, and the challenges of selecting the...

multiple myeloma

Beth M. Faiman, PhD, MSN, CNP, AOCN, on Managing Multiple Myeloma

Beth M. Faiman, PhD, MSN, CNP, AOCN, of the Cleveland Clinic, discusses working with patients with multiple myeloma to minimize the toxicity of their treatment and improve their outcomes.

lymphoma

Julie M. Vose, MD, MBA, on Highlights of Pan Pacific Lymphoma 2016

Julie M. Vose, MD, MBA, of the University of Nebraska Medical Center, discusses the key presentations at the 2016 Pan Pacific Lymphoma Conference.

lymphoma

Bruce D. Cheson, MD, and Julie M. Vose, MD, MBA, on Staging Lymphoma

Bruce D. Cheson, MD, of Georgetown University Hospital, and Julie M. Vose, MD, MBA, of the University of Nebraska Medical Center, discuss whether lymphoma should be staged with a positron emission tom...

lymphoma

David G. Maloney, MD, PhD, on Lymphomas: Treatment With CAR T Cells

David G. Maloney, MD, PhD, of Fred Hutchinson Cancer Research Center, discusses the efficacy of chimeric antigen receptor (CAR) T cells for lymphoma and their toxicity.

lymphoma

Stephen M. Ansell, MD, PhD, on Precision Immunotherapy for Refractory Hodgkin Lymphoma

Stephen M. Ansell, MD, PhD, of the Mayo Clinic, discusses the role of checkpoint inhibitors in Hodgkin lymphoma and the efficacy of nivolumab and pembrolizumab.

leukemia
lymphoma

Susan M. O’Brien, MD, on ALL/Lymphoma: Upfront and Salvage Treatments in Older Patients

Susan M. O’Brien, MD, of the University of California, Irvine, discusses the challenges of treating older patients with acute lymphoblastic leukemia and lymphoma, and the positive results with newer r...

lymphoma

Kieron M. Dunleavy, MD, on Lymphomas: Genomics and Genetics

Kieron M. Dunleavy, MD, of the National Cancer Institute, discusses the genomic landscape of aggressive lymphomas and how this is informing therapy decisions.

lymphoma

Andrew D. Zelenetz, MD, on Diffuse Large B-Cell Lymphoma: CHOP-R and EPOCH-R?

Andrew D. Zelenetz, MD, of Memorial Sloan Kettering Cancer Center, discusses the pros and cons of these two regimens, with or without another agent, in diffuse large B-cell lymphoma.

Advertisement

Advertisement



;
Advertisement